Note 9 - Significant Risks and Uncertainties	12 Months Ended
Jun. 30, 2020
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	Note 9 . Significant Risks and Uncertainties (a) Concentrations of Credit Risk-Cash. The Company maintains balances at several financial institutions. Deposits at each institution are insured by the Federal Deposit Insurance Corporation up to $250. As of June 30, 2020, the Company had $70 in uninsured deposits at these financial institutions. (b) Concentrations of Credit Risk-Receivables. The Company routinely assesses the financial strength of its customers and, based upon factors surrounding the credit risk of its customers, establishes an allowance for uncollectible accounts and, as a consequence, believes that its accounts receivable credit risk exposure beyond such allowances is limited. The Company does not require collateral in relation to its trade accounts receivable credit risk. (c) Major Customers. For the fiscal years ended June 30, 2020 and 2019, approximately 92% and 91% of consolidated net sales, respectively, were derived from two customers. These two customers are in the Company's Contract Manufacturing Segment and represent approximately 69% and 26% of this segment's net sales in each of the fiscal years ended June 30, 2020 and 2019. Accounts receivable from these two major customers represented approximately 92% and 88% of total net accounts receivable as of June 30, 2020 and 2019, respectively. One other customer in the Other Nutraceutical Segment, while not a significant customer of the Company's consolidated net sales, represented approximately 10% and 13% of net sales of the Other Nutraceutical Segment in the fiscal years ended June 30, 2020 and 2019, respectively. The loss of any of these customers could have an adverse effect on the Company's operations. Major customers are those customers who account for more than 10% of net sales. (d) Business Risks. The Company insures its business and assets against insurable risks, to the extent that it deems appropriate, based upon an analysis of the relative risks and costs. The Company believes that the risk of loss from non-insurable events would not have a material adverse effect on the Company's operations as a whole. The raw materials used by the Company are primarily commodities and agricultural-based products. Raw materials used by the Company in the manufacture of its nutraceutical products are purchased from independent suppliers. Raw materials are available from numerous sources and the Company believes that it will continue to obtain adequate supplies. Approximately 72% the Company's employees are covered by a union contract and are employed in its New Jersey facilities. The contract was renewed effective September 1, 2019 and will expire on August 31, 2022. The COVID- 19, or coronavirus, outbreak has the potential to cause a disruption in the Company's supply chain. Currently, some of our suppliers of certain materials used in the production of our supplements are located in China and other impacted countries or other states within the United States. Most of these materials may be obtained from more than one supplier. However, due to port closures and other restrictions resulting from the coronavirus outbreak throughout the world, these suppliers, located both inside and outside of the United States, may have limited supply of the materials, which will cause the price of the materials to increase. These and other disruptions would likely impact the Company's sales and operating results. If the Company is unable to obtain the necessary materials to produce a supplement within the Company's standard lead times, it may delay the production and shipment of those supplements, thereby shifting the timing of recognizing the resulting sale to the Company's customers. In addition, the significant outbreak of this contagious disease in the human population has resulted in a widespread health crisis that could adversely affect the economies and financial markets of many countries, resulting in an economic downturn that could affect demand for the Company's products and impact the Company's operating results. The Company does not currently anticipate any negative impact to its margins resulting from the coronavirus outbreak, however; if the Company is unable to obtain the necessary materials to produce a supplement within its standard lead times or the necessary safety and cleaning supplies it may delay the production and shipment of those supplements to its customers, thereby shifting the timing of recognizing the resulting sale to its customers.

Note

. Significant Risks and Uncertainties

(a)

Concentrations of Credit Risk-Cash.

The Company maintains balances at several financial institutions. Deposits at each institution are insured by the Federal Deposit Insurance Corporation up to

$250.

As of

June 30, 2020,

the Company had

$70

in uninsured deposits at these financial institutions.

(b) Concentrations of Credit Risk-Receivables.

The Company routinely assesses the financial strength of its customers and, based upon factors surrounding the credit risk of its customers, establishes an allowance for uncollectible accounts and, as a consequence, believes that its accounts receivable credit risk exposure beyond such allowances is limited. The Company does

not

require collateral in relation to its trade accounts receivable credit risk.

For the fiscal years ended

June 30, 2020

and

2019,

approximately

92%

and

91%

of consolidated net sales, respectively, were derived from

two

customers. These

two

customers are in the Company's Contract Manufacturing Segment and represent approximately

69%

and

26%

of this segment's net sales in each of the fiscal years ended

June 30, 2020

and

2019.

Accounts receivable from these

two

major customers represented approximately

92%

and

88%

of total net accounts receivable as of

June 30, 2020

and

2019,

respectively.

One other customer in the Other Nutraceutical Segment, while

not

a significant customer of the Company's consolidated net sales, represented approximately

10%

and

13%

of net sales of the Other Nutraceutical Segment in the fiscal years ended

June 30, 2020

and

2019,

respectively. The loss of any of these customers could have an adverse effect on the Company's operations. Major customers are those customers who account for more than

10%

of net sales.

(d) Business Risks.

The Company insures its business and assets against insurable risks, to the extent that it deems appropriate, based upon an analysis of the relative risks and costs. The Company believes that the risk of loss from non-insurable events would

not

have a material adverse effect on the Company's operations as a whole.

The raw materials used by the Company are primarily commodities and agricultural-based products. Raw materials used by the Company in the manufacture of its nutraceutical products are purchased from independent suppliers. Raw materials are available from numerous sources and the Company believes that it will continue to obtain adequate supplies.

Approximately

72%

the Company's employees are covered by a union contract and are employed in its New Jersey facilities. The contract was renewed effective

September 1, 2019

and will expire on

August 31, 2022.

The COVID-

19,

or coronavirus, outbreak has the potential to cause a disruption in the Company's supply chain. Currently, some of our suppliers of certain materials used in the production of our supplements are located in China and other impacted countries or other states within the United States. Most of these materials

may

be obtained from more than

one

supplier. However, due to port closures and other restrictions resulting from the coronavirus outbreak throughout the world, these suppliers, located both inside and outside of the United States,

may

have limited supply of the materials, which will cause the price of the materials to increase. These and other disruptions would likely impact the Company's sales and operating results. If the Company is unable to obtain the necessary materials to produce a supplement within the Company's standard lead times, it

may

delay the production and shipment of those supplements, thereby shifting the timing of recognizing the resulting sale to the Company's customers. In addition, the significant outbreak of this contagious disease in the human population has resulted in a widespread health crisis that could adversely affect the economies and financial markets of many countries, resulting in an economic downturn that could affect demand for the Company's products and impact the Company's operating results.

The Company does

not

currently anticipate any negative impact to its margins resulting from the coronavirus outbreak, however; if the Company is unable to obtain the necessary materials to produce a supplement within its standard lead times or the necessary safety and cleaning supplies it

may

delay the production and shipment of those supplements to its customers, thereby shifting the timing of recognizing the resulting sale to its customers.